Unlabelled: The aim of this study is to investigate plasma concentration of visfatin and transforming growth factor Β1 (TGF-Β1) in three groups of patients: primary biliary cirrhosis (PBC), non-alcoholic fatty liver disease (NAFLD) and toxic cirrhosis (TC). We qualified the patients into the study and assigned them to the appropriate group according to clinical examination, laboratory tests and ultrasound imaging technic (US). We showed that plasma concentrations of visfatin in PBC, NAFLD and TC group were respectively 1.41 ± 1.76 ng/mL, 1.22 ± 1.08 ng/mL and 0.70 ± 1.22 ng/mL. Plasma concentration of visfatin was significantly lower in TC group than in others both (p ± 0.017). The differences of visfatin concentration between NAFLD and TC group were not statistically significant. The values of TGF-Β1 in PBC, NAFLD and TC group were respectively 21031 ± 7822 pg/mL, 21588 ± 12639 pg/mL, and 9678 ± 4757 pg/mL. The statistical analysis showed that the value of cirrhotic group was significantly (p ±0.017) lower compared to both others groups. The difference between PBC and NAFLD was insignificant.
In Conclusion: Despite the PBC and NAFLD are the diseases of different pathogenesis and origin, plasma concentration of visfatin and TGF-Β1 were similar in these both groups but significantly lower in TC probably due to decreased activity as well as number of cells producing these cytokines in the cirrhotic liver.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Bidirectional Mendelian randomization links gut microbiota to primary biliary cholangitis.
Sci Rep
November 2024
Department of Hepatology, ShuGuang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China.
Primary biliary cholangitis (PBC) and gut microbiota (GM) are epidemiologically correlated but the causal inter-relationships remain poorly understood. We aim to explore the causal relationships between GM and PBC. Using the MiBioGen consortium, GWAS data for GM at the species level and the largest publicly available PBC GWAS data to date, we performed a bidirectional two-sample Mendelian randomization by the inverse variance weighted, MR-Egger, weighted median, weighted model and MR-PRESSO to elucidate the potential causal role of GM in PBC.
View Article and Find Full Text PDFAdiponectin as a biomarker in liver cirrhosis-A systematic review and meta-analysis.
Eur J Clin Invest
January 2025
2nd Department of Internal Medicine, "Iuliu Hatieganu" University of Medicine and Pharmacy, Cluj-Napoca, Romania.
Article Synopsis
- Adiponectin is a promising non-invasive biomarker for liver cirrhosis, reflecting inflammation and metabolic changes, but its role remains unclear due to conflicting findings.
- A systematic review was conducted using 16 studies with 2617 participants, finding that adiponectin levels were significantly higher in liver cirrhosis patients, particularly in those classified as Child-Pugh B.
- The study concludes that while adiponectin is elevated in advanced liver cirrhosis, there are no significant differences when compared to hepatocellular carcinoma (HCC) patients, highlighting its potential as a diagnostic and prognostic tool.
Efficacy and safety of palliative treatment in patients with autoimmune liver disease-associated hepatocellular carcinoma.
Ann Hepatol
October 2024
Department of Internal Medicine and Gastroenterology, University Medical Center Hamburg-Eppendorf, Martinistrasse 52, 20246 Hamburg, Germany; European Reference Network on Hepatological Diseases (ERN RARE-LIVER).
Introduction And Objectives: Autoimmune liver diseases (AILD) are rare causes hepatocellular carcinoma (HCC), and data on the efficacy and tolerability of anti-tumor therapies are scarce. This pan-European study aimed to assess outcomes in AILD-HCC patients treated with tyrosine kinase inhibitors (TKIs) or transarterial chemoembolization (TACE) compared with patients with more common HCC etiologies, including viral, alcoholic or non-alcoholic fatty liver disease.
Materials And Methods: 107 patients with HCC-AILD (AIH:55; PBC:52) treated at 13 European centres between 1996 and 2020 were included.
The overlap with metabolic dysfunction-associated steatotic liver disease negatively affects outcomes of primary biliary cholangitis.
Aliment Pharmacol Ther
September 2024
Gastroenterology and Hepatology Department, La Paz University Hospital, Madrid, Spain.
Background And Aims: The relationship between primary biliary cholangitis (PBC) and metabolic dysfunction-associated steatotic liver disease, and its impact on treatment response and prognosis, remains underexplored.
Methods: Patient cohort from two centres comprising long-term follow-up data. All patients had histologically confirmed PBC.
Coexistence of metabolic-associated fatty liver disease and autoimmune or toxic liver disease.
Eur J Gastroenterol Hepatol
July 2024
Clinic of Gastroenterology, Abdominal Center, Helsinki University Hospital and University of Helsinki.
Fatty liver disease (FLD) affects approximately 25% of global adult population. Metabolic-associated fatty liver disease (MAFLD) is a term used to emphasize components of metabolic syndrome in FLD. MAFLD does not exclude coexistence of other liver disease, but impact of coexisting MAFLD is unclear.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!